Cargando…

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tobinai, Kensei, Klein, Christian, Oya, Naoko, Fingerle-Rowson, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331088/ https://www.ncbi.nlm.nih.gov/pubmed/28004361 http://dx.doi.org/10.1007/s12325-016-0451-1

Ejemplares similares

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
por: Herting, Frank, et al.
Publicado: (2014)

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
por: Bakkour, Waseem, et al.
Publicado: (2012)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant
por: Redfield, Robert R., et al.
Publicado: (2019)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
por: Ysebaert, L, et al.
Publicado: (2015)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
por: Blase, Jennifer R., et al.
Publicado: (2022)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

A Novel Multidrug Resistance in Cultured Leukemia and Lymphoma Cells Detected by a Monoclonal Antibody to 85‐kDa Protein, MRK20
por: Ohtsu, Tomoko, et al.
Publicado: (1989)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
por: Calò, Federica, et al.
Publicado: (2022)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
por: Ohmachi, Ken, et al.
Publicado: (2018)

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL
por: Chu, Yaya, et al.
Publicado: (2020)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
por: Elias, Shlomo, et al.
Publicado: (2018)

MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models
por: Fingerle-Rowson, Günter, et al.
Publicado: (2007)

Multidrug Resistance in Cultured Human Leukemia and Lymphoma Cell Lines Detected by a Monoclonal Antibody, MRK16
por: Ishida, Yasushi, et al.
Publicado: (1989)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment
por: Awasthi, Aradhana, et al.
Publicado: (2017)

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
por: van Bommel, Peter E., et al.
Publicado: (2017)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series
por: Rüfenacht, Susanne, et al.
Publicado: (2022)

Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013)

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells
por: Latour, Simon, et al.
Publicado: (2019)

The Role of Different Supplements in Expression Level of Monoclonal Antibody against Human CD20
por: Mahboudi, Fereidoun, et al.
Publicado: (2013)

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies
por: Winiarska, Magdalena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r0alpluk0u740tedg18fem5nmd